Alkem Medtech announced plans to acquire up to 55 percent stake in Swiss medical devices company Occlutech Holding AG for €99.4 million (approximately ₹1,074 crore). The transaction, subject to statutory and regulatory approvals, marks Alkem’s formal entry into the advanced cardiovascular devices segment. Alkem Medtech, a wholly owned subsidiary of Alkem Laboratories, has executed a binding offer for the majority stake. The acquisition is expected to close by June 2026, following regulatory clearances and fulfilment of customary conditions, including foreign investment approvals in certain jurisdictions.
Strategic Entry into Advanced Cardiovascular Devices
With this acquisition, Alkem Medtech will expand into high-value, minimally invasive cardiac implant technologies. Occlutech develops, manufactures, and commercialises devices used in treating congenital heart disease, stroke prevention, and heart failure.
Notably, Occlutech ranks as the second-largest company in Europe and the third-largest globally in the minimally invasive cardiac implants segment. The company operates:
*Manufacturing and R&D facilities in Germany and Turkey
*A global distribution hub in Sweden
*Clinical operations in the United States
Through this footprint, Occlutech has built a strong presence in regulated and innovation-driven markets.
Building a Global MedTech Platform
BN Singh, Executive Chairman of Alkem Laboratories, emphasised the long-term strategic vision behind the move. He stated that the acquisition reinforces Alkem’s ambition to become a global player in medical devices. It aims to replicate the success the company has achieved in pharmaceuticals.
Kaustav Banerjee, CEO of Alkem Medtech, highlighted Occlutech’s strengths in structural heart devices, experienced leadership, world-class R&D and manufacturing capabilities, and a strong quality and regulatory framework. He noted that these capabilities provide a solid foundation for Alkem’s expansion into cardiology and enable sustainable long-term growth.
Tor Peters, CEO of Occlutech, said that over the past 23 years, the company has built a patient-centric and innovation-driven organisation. He added that these values align closely with Alkem’s growth strategy.
MedTech: A Natural Extension of Alkem’s Growth Strategy
Sandeep Singh, Managing Director of Alkem Laboratories, described MedTech as a natural extension of the company’s pharmaceutical business. He added that alongside Enzene Biosciences, Alkem’s biotech arm, Alkem Medtech is expected to emerge as a meaningful growth pillar in the coming years.
Outlook
Overall, the proposed acquisition signals Alkem’s strategic diversification beyond pharmaceuticals into high-growth medical devices. As reported by thehindubusinessline.com, the company plans to combine Occlutech’s technological expertise with Alkem’s scale and global reach. Through this strategy, it aims to build a strong foothold in advanced cardiovascular care and position itself as an emerging global MedTech player.
